Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity-Reference-Cited by-同舟云学术

Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity

Published:2003-01 Issue:1 Volume:1609 Page:102-108
ISSN:0005-2736
Container-title:Biochimica et Biophysica Acta (BBA) - Biomembranes
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Biomembranes

Author:

Charrois Gregory J.R.,Allen Theresa M.

Publisher

Elsevier BV

Subject

Cell Biology,Biochemistry,Biophysics

Reference42 articles.

1. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.

2. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

3. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

4. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin

5. Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLGA nanomedical consignation: A novel approach for the management of prostate cancer;International Journal of Pharmaceutics;2024-03

2. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy;International Journal of Pharmaceutics;2024-02

3. Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development;Biomacromolecules;2024-01-19

4. Nanotoxicological profiles of clinically approved nanoplatforms;Beni-Suef University Journal of Basic and Applied Sciences;2023-12-16

5. Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?;Pharmaceutics;2022-10-28